银屑病患者之间的HLA - Cw6状态与治疗反应
HLA-Cw6 Status and Treatment Responses Between Psoriasis Patients.
作者信息
Temel Berkay, Adisen Esra, Gonen Sevim
机构信息
Dermatology and Venereology, Ankara Training and Research Hospital, Ankara, Turkey.
Dermatology and Venerology, Gazi University Faculty of Medicine, Ankara, Turkey.
出版信息
Indian J Dermatol. 2021 Nov-Dec;66(6):632-637. doi: 10.4103/ijd.IJD_282_21.
BACKGROUND
The number of treatment options in psoriasis has increased considerably, so biomarkers should be searched to assist in the selection of the optimal treatment agent. The most common of these biomarkers is HLA-Cw6.
OBJECTIVE
The aim was to determine whether there is a relationship between HLA-Cw6-positivity (HLA-Cw6-POS) and the response of treatment agents in psoriasis.
METHODS
Blood samples of 124 patients were subjected to genetic study for HLA-Cw6.
RESULTS
Psoriasis area severity index (PASI) score of more than 75% (PASI75) response was received in 34 (73.9%) of the HLA-Cw6-POS methotrexate-treated patients, 30 (78.9%) of the HLA-Cw6-POS cyclosporine-treated patients, and 8 (37.5%) of the HLA-Cw6-POS acitretin-treated patients. The differences were not statistically significant ( = 0.634-0.071-0.409). PASI75 response was received in 73 (68.2%) of the HLA-Cw6-POS patients in patients treated with conventional agents. In adalimumab-treated patients, PASI75 response was received in 8 (53.3%) of the HLA-Cw6-POS patients, 6 (75%) of the HLA-Cw6-POS infliximab-treated patients, and 4 (57.1%) of the HLA-Cw6-POS ustekinumab-treated patients. The differences were not statistically significant ( = 0.245-1.00-0.322). PASI75 response was received in 24 (64.9%) of the HLA-Cw6-POS and 33 (84.6%) of HLA-Cw6 negative (HLA-Cw6-NEG) patients with biological agents. The biological agent response was statistically significantly lower in HLA-Cw6-POS.
CONCLUSION
None of the agents were affected by HLA-Cw6. When biological agents were evaluated collectively, the treatment response of HLA-Cw6-POS patients was lower.
背景
银屑病的治疗选择数量显著增加，因此应寻找生物标志物以协助选择最佳治疗药物。其中最常见的生物标志物是HLA - Cw6。
目的
旨在确定HLA - Cw6阳性（HLA - Cw6 - POS）与银屑病治疗药物反应之间是否存在关联。
方法
对124例患者的血样进行HLA - Cw6基因研究。
结果
HLA - Cw6 - POS的甲氨蝶呤治疗患者中，34例（73.9%）获得了银屑病面积和严重程度指数（PASI）评分超过75%（PASI75）的反应；HLA - Cw6 - POS的环孢素治疗患者中，30例（78.9%）获得该反应；HLA - Cw6 - POS的阿维A治疗患者中，8例（37.5%）获得该反应。差异无统计学意义（= 0.634 - 0.071 - 0.409）。在接受传统药物治疗的患者中，HLA - Cw6 - POS患者中有73例（68.2%）获得PASI75反应。在接受阿达木单抗治疗的患者中，HLA - Cw6 - POS患者中有8例（53.3%）获得PASI75反应；HLA - Cw6 - POS的英夫利昔单抗治疗患者中，6例（75%）获得该反应；HLA - Cw6 - POS的优特克单抗治疗患者中，4例（57.1%）获得该反应。差异无统计学意义（= 0.245 - 1.00 - 0.322）。使用生物制剂的患者中，HLA - Cw6 - POS患者有24例（64.9%）获得PASI75反应，HLA - Cw6阴性（HLA - Cw6 - NEG）患者有33例（84.6%）获得该反应。HLA - Cw6 - POS患者的生物制剂反应在统计学上显著较低。
结论
没有一种药物受HLA - Cw6影响。当对生物制剂进行综合评估时，HLA - Cw6 - POS患者的治疗反应较低。
Zotero 插件